What Is Xeomin?
Xeomin is a botulinum toxin type A used for the treatment of frown lines and crow’s feet by relaxing the facial muscles. These muscles contract when you smile, talk, or laugh, which can lead to wrinkles and other skin changes over time. Xeomin reduces these effects, making the skin smoother, leading to a more refreshed and relaxed appearance.
Xeomin is the next generation in botulinum toxin wrinkle treatment. It is the only purified wrinkle treatment botulinum toxin available today and is free from complexing proteins. Complexing proteins are formed during the fermentation process of every botulinum toxin (e.g. Botox, Dysport). They are surplus and have no therapeutic benefits, they can in some cases lead to antibody formation and secondary treatment failure.
How Does It Work?
Xeomin acts on the nerve endings in muscle tissue to reduce the ability of the muscle to contract, hence improving the look of frown lines between the eyebrows, horizontal forehead lines or crow’s feet around the eyes.
What Is The Treatment Procedure Like?
As it is an injection, it is a non surgical procedure that usually requires little recovery time.
What's The Difference Between Xeomin & Botox?
This is a great question. We've put together a in-depth blog post that answers this question in more detail here...
Xeomin before and after...
This was achieved using Xeomin botulinum toxin in just one appointment.
*Please note results will vary between individual patients.
Is Xeomin Suitable For Me?
There are some conditions (including other medicines you may take to treat these conditions) that may render you unsuitable for these injections; therefore, you will need to provide comprehensive information to our trained Xeomin staff at Dent1st.
Is Xeomin Safe?
All medicines have risks and benefits. Together with you, your Xeomin clinician will weigh up the risks of you using this medicine against the benefits you expect it will have for you.
How Soon Can I See Results?
The onset of improvement varies between individuals. The treatment effect can appear as early as a few days or may take about 2 weeks.
Xeomin Abridged information for DTCA
Xeomin® is a Prescription Medicine containing 50, 100 LD50 Units of clostridium botulinum Type A toxin complex for injection. It is used for the treatment of frown lines on the forehead, lateral periorbital lines and horizontal forehead lines in adults. It should be administered only by trained medical professionals.
Talk to your specialist about the benefits/risks of this procedure in appearance medicine. Xeomin treatment lasts about four months and further courses of treatment may be necessary. Cautions: Generalised disorders of muscle activity; Infection or inflammation at the proposed injection sites, pregnancy and lactation. Possible side effects: headache, pain, swelling or infection at injection site, local muscle weakness including drooping eye lids, lack of feeling & nausea. You will need to pay for this medicine.
Discuss with your specialist if Xeomin is right for you. For more information or for a copy of CMI please contact the NZ distributor: NZMS Ltd: 2a Fisher Crescent, Mt Wellington, Auckland, Ph 09 259 4062.TAPS NA9792.
Xeomin HCP abridged datasheet
is a Prescription Medicine. Please review full Product Information before
prescribing, available from New Zealand Medical & Scientific Ltd (NZMS) on 09 259 4062.
(Incobotulinumtoxin A, purified Botulinum toxin type A, free from complexing proteins,
powder for solution for injection). 50, 100 LD50 Units. Indications: In adults, for the treatment of
cervical dystonia; blepharospasm; post-stroke spasticity of the upper limb and upper facial lines
including forehead, periorbital (crow’s feet) and glabellar lines in adults. Contraindications:
Hypersensitivity to ingredients; generalised disorders of muscle activity (e.g. myasthenia gravis,
Lambert-Eaton Syndrome); Infection or inflammation at the proposed injection sites. Precautions:
bleeding disorders; local and distant spread of toxin effect; pre-existing neuromuscular disorders;
hypersensitivity reactions, antibody formation; lack of interchangeability between botulinum toxin
products; mild to severe dysphagia, aspiration and dyspnoea; muscle weakness (neck); swallowing,
speech or respiratory disorders; avoid injection through pen marks, into blood vessels, near levator
palpebrae superioris, inferior oblique and medial injections into the lower lid; ptosis; diplopia; reduced
blinking; contains albumin (human); pregnancy (Cat B3); lactation; children (not recommended);
driving/using machines; others, see full PI. Interactions with other medicines: Aminoglycoside
antibiotics; anticoagulants or those with similar effect; other agents interfering with neuromuscular
transmission, e.g., tubocurarine-type muscle relaxants. Adverse effects: Cervical Dystonia: neck
pain, muscular weakness, musculoskeletal pain and stiffness, dysphagia, nausea, headache, injection
site pain, Blepharospasm: dry eyes, eyelid ptosis, vision blurred, dry mouth, Poststroke spasticity:
muscle weakness Upper facial lines: headache, risk of eyelid, brow or lip ptosis; others, see full
PI. Dosage and Administration: For intramuscular injection, single use in one patient only. Unit
doses recommended for Xeomin are not interchangeable with those for other preparations of
botulinum toxin. Reconstitute with sodium chloride 9 mg/mL (0.9%) solution for injection (see full PI
for dilutions). The optimum dose and number of injection sites in the treated muscle(s) should be
individualised for each patient and determined by the treating doctor. Cervical dystonia: 0.1 to 0.5
mL/site; max 50 U/site; max 300 U/treatment session. Treatment intervals should be determined
based on the actual clinical need of the individual patient and generally no more frequent than every 6
weeks. Blepharospasm: 0.05-0.1 mL/ site; max 35 U/eye for pre-treated patients, if the previous dose
of botulinum toxin is not known; max 25 U/eye for treatment naïve patients; max 100 U per treatment
session. Treatment intervals should be determined based on the actual clinical need of the individual
patient and generally no more frequent than every 6 weeks. Post-stroke spasticity: max 400
U/treatment session; treatment intervals should be determined based on the actual clinical need of
the individual patient and generally no more frequent than every 12 weeks. Upper facial lines:
Glabellar -0.1 mL/site; max 30 U/treatment session; Periorbital – 0.1ml per site max 12 U per side;
Forehead – total dose 10 to 20 U ; treatment intervals should be determined based on the actual
clinical need of the individual patient and generally no more frequent than every 3 months; see full PI.
Medsafe-approved 18 December 2014. XEOMIN is a registered trademark of Merz Pharma GmbH &
Co. KGaA. Copyright ©2014. Prepared 18 February 2015. Xeomin is an unfunded medicine. For more
information please contact the New Zealand Distributor: New Zealand Medical and Scientific Ltd, 2a
Fisher Crescent, Mt Wellington, Auckland, Phone 09 259 4062. TAPS NA9800.